Literature DB >> 15364743

Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism.

Hiroshi Inoue1, Takashi Nozawa, Ken Okumura, Lee Jong-Dae, Akihiko Shimizu, Katsusuke Yano.   

Abstract

STUDY
OBJECTIVES: The aim of this study was to investigate whether risk factors for embolism would promote thrombus formation in patients with nonvalvular atrial fibrillation (NVAF).
METHODS: Hemostatic markers for platelet activity (ie, platelet factor-4 and beta-thromboglobulin [TG]), thrombotic status (ie, prothombin fragments 1 and 2), and fibrinolytic status (ie, d-dimer) were determined in 246 patients with NVAF (mean age, 66.1 years) and 111 control subjects without NVAF (68.3 years).
RESULTS: The beta-TG level was higher in NVAF patients than in control subjects. D-dimer levels were higher in NVAF patients having risk factors (mean [+/- SE] d-dimer level, 158.6 +/- 9.2 ng/mL) than in those without risk factors (mean d-dimer level, 92.1 +/- 6.7 ng/mL; p < 0.01) and in control subjects (mean d-dimer level: control subjects with risk factors, 79.1 +/- 10.3 ng/mL; control subjects without risk factors, 31.0 +/- 7.4 ng/mL; p < 0.01). NVAF (odds ratio [OR], 3.94; 95% confidence interval [CI], 1.87 to 8.30; p = 0.0003) and age of >/= 75 years (OR, 5.68; 95% CI, 2.87 to 11.23; p < 0.0001) emerged as predictors of elevated levels of d-dimer, and only NVAF (OR, 10.30; 95% CI, 5.67 to 18.72; p < 0.0001) emerged as a predictor of elevated levels of beta-TG.
CONCLUSIONS: NVAF patients whose conditions were complicated with risk factors for embolism could be in the prothrombotic state. Advanced age is a strong predictor of the prothrombotic state in NVAF patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364743     DOI: 10.1378/chest.126.3.687

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  19 in total

1.  Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study.

Authors:  Margaret C Fang; Daniel E Singer; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Alan S Go
Journal:  Circulation       Date:  2005-09-12       Impact factor: 29.690

Review 2.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

3.  D-Dimer assay as a non invasive test for the diagnosis of left atrial Thrombi in Indian patients with Rheumatic MS.

Authors:  M Rajappa; T N Sunil Roy; A Raj; V Trehan; V Mallika
Journal:  Afr Health Sci       Date:  2013-09       Impact factor: 0.927

Review 4.  Antiplatelet therapy for stroke prevention in atrial fibrillation.

Authors:  Nadish Garg; Arun Kumar; Greg C Flaker
Journal:  Mo Med       Date:  2010 Jan-Feb

Review 5.  Interventional and surgical occlusion of the left atrial appendage.

Authors:  Etem Caliskan; James L Cox; David R Holmes; Bernhard Meier; Dhanunjaya R Lakkireddy; Volkmar Falk; Sacha P Salzberg; Maximilian Y Emmert
Journal:  Nat Rev Cardiol       Date:  2017-08-10       Impact factor: 32.419

6.  Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage.

Authors:  Meredith P Murphy; Joji B Kuramatsu; Audrey Leasure; Guido J Falcone; Hooman Kamel; Lauren H Sansing; Christina Kourkoulis; Kristin Schwab; Jordan J Elm; M Edip Gurol; Huy Tran; Steven M Greenberg; Anand Viswanathan; Christopher D Anderson; Stefan Schwab; Jonathan Rosand; Fu-Dong Shi; Steven J Kittner; Fernando D Testai; Daniel Woo; Carl D Langefeld; Michael L James; Sebastian Koch; Hagen B Huttner; Alessandro Biffi; Kevin N Sheth
Journal:  Stroke       Date:  2018-11       Impact factor: 7.914

7.  Cardioembolic stroke in atrial fibrillation-rationale for preventive closure of the left atrial appendage.

Authors:  Boris Leithäuser; Jai-Wun Park
Journal:  Korean Circ J       Date:  2009-11-30       Impact factor: 3.243

Review 8.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

9.  Paroxysmal supraventricular tachycardia and the risk of ischemic stroke.

Authors:  Hooman Kamel; Mitchell S V Elkind; Prashant D Bhave; Babak B Navi; Peter M Okin; Costantino Iadecola; Richard B Devereux; Matthew E Fink
Journal:  Stroke       Date:  2013-04-30       Impact factor: 7.914

10.  Relevance of transthoracic left atrial appendage wall velocity measurement in addition to left atrial volume for noninvasive and quantitative assessment of left atrial thrombogenesis in patients with atrial fibrillation and normal D-dimer levels.

Authors:  Naoyasu Yoshida; Mitsunori Okamoto; Hidekazu Hirao; Kazuyoshi Suenari; Kiyomi Nanba; Mio Uchida; Ryo Yamazato; Yuichiro Watari; Yukihiro Fukuda; Hironori Ueda
Journal:  J Med Ultrason (2001)       Date:  2015-12-14       Impact factor: 1.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.